Health Monitor Liechtenstein
SEE OTHER BRANDS

Your health and wellness news reporter from Liechtenstein

Press Releases

Looking for more press releases? Explore our full press release archive by date to access past announcements, news updates, and media releases published on Health Monitor Liechtenstein.

Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates

Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates

SHANGHAI, March 28, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization...

Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above

Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above

With this extension, IXCHIQ®, the first vaccine against the chikungunya virus (CHIKV), is now available for administration for individuals 12 years of age and older in the European Union (EU). Saint Herblain (France), April 1, 2025 – Valneva SE...

Dental Consumables Market Growth Outlook: USD 30.47 Billion in 2024 to USD 75.02 Billion by 2032 at 12.4% CAGR

Dental Consumables Market Growth Outlook: USD 30.47 Billion in 2024 to USD 75.02 Billion by 2032 at 12.4% CAGR

Key Companies covered in dental consumables market are Dentsply Sirona, Institut Straumann AG, ZimVie, Inc., Henry Schein, Inc., Cortex, & others. NY, UNITED STATES, April 9, 2025 /⁨EINPresswire.com⁩/ -- The global dental consumables market was...

Global Digital Dentistry Market Report: Projected Growth from USD 4.60 Billion in 2024 to USD 9.22 Billion by 2032

Global Digital Dentistry Market Report: Projected Growth from USD 4.60 Billion in 2024 to USD 9.22 Billion by 2032

Leading companies in the digital dentistry market include 3Shape A/S, Align Technology, Inc., Dentsply Sirona, Envista, Planmeca Oy, AG, and more. NJ, UNITED STATES, April 1, 2025 /⁨EINPresswire.com⁩/ -- The global digital dentistry market size...

Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®

Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®

If granted, IXCHIQ® will become the first vaccine against the chikungunya virus (CHIKV) available in the EU for adolescents 12 years of age and older Saint Herblain (France), February 28, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a...

Fish Fund Steering Committee advances work on Call for Proposals, welcomes new members

Fish Fund Steering Committee advances work on Call for Proposals, welcomes new members

The agreement on next steps brings the Steering Committee closer to opening its first Call for Proposals. The Fund will receive funding requests for project grants that will support developing and least developed country (LDC) members to implement...

Radiance Biopharma Enters Exclusive License For ROR-1 Targeted Antibody Drug Conjugate

Radiance Biopharma Enters Exclusive License For ROR-1 Targeted Antibody Drug Conjugate

BOSTON, Massachusetts, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc., ("Radiance" or the "Company"), a biotechnology company, today announced that it has entered into an exclusive License agreement with CSPC Megalith Biopharmaceutical...

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

BASEL, Switzerland and VANCOUVER, British Columbia and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio...

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

BASEL, Switzerland and VANCOUVER, B.C. and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio (a...

Dental Prosthetics Market Projected to Reach USD 15.87 Billion, with a Robust 5.72% CAGR Till 2034

Dental Prosthetics Market Projected to Reach USD 15.87 Billion, with a Robust 5.72% CAGR Till 2034

Dental Prosthetics Market Insights: Rising demand due to aging population and aesthetic dentistry trends EU, EUROPEAN UNION, SWEDEN, January 14, 2025 /⁨EINPresswire.com⁩/ -- Market Research Future Latest Industry Insights on Dental Prosthetics...

Dental Consumables Market Size to Worth USD 75.02 billion by 2032, CAGR of 12.4% during 2025-2032

Dental Consumables Market Size to Worth USD 75.02 billion by 2032, CAGR of 12.4% during 2025-2032

Discover the latest trends in the global dental consumables market, explore key players like Dentsply Sirona, Straumann, 3M, ZimVie, Osstem Implant, and more. PUNE, MAHARAHTRA, INDIA, March 5, 2025 /⁨EINPresswire.com⁩/ -- The global dental...

bonyf R&D presents its two latest innovations at IDS 2025 in Cologne

bonyf R&D presents its two latest innovations at IDS 2025 in Cologne

bonyf R&D presents its two latest oral care innovations at IDS 2025 in Cologne from 25-29 March 2025 at the IDS. Visit bonyf at the IDS in Hall 5.2, Booth 131. bonyf (MLBON:BE6333353298-XMLI) KNOKKE-HEIST, KNOKKE-HEIST, BELGIUM, March 6, 2025...

Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and Older

Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and Older

First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old. The virus-like particle (VLP) single-dose chikungunya vaccine is expected to launch in key European markets in the first half of 2025, pending final marketing...

Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million 

Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million 

Saint Herblain (France), January 30, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the signing of a new $32.8 million contract with the United States (U.S.) Department of Defense (DoD) for the...

InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)

InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)

JENA, Germany, Jan. 15, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the European Commission (EC) has granted...

Opterro, Inc. and Polytec GmbH Announce Strategic Distribution Agreement Across Eight European Countries

Opterro, Inc. and Polytec GmbH Announce Strategic Distribution Agreement Across Eight European Countries

Under this agreement, Polytec will serve as Opterro’s distribution partner across several key European markets. SILICON VALLEY, CA, UNITED STATES, April 23, 2025 /⁨EINPresswire.com⁩/ -- Opterro, Inc. (www.opterro.com), a global leader in advanced...

The European Magazine releases its Philanthropy Focus Supplement, featuring Nigel Mansell CBE's dedication to UK Youth

The European Magazine releases its Philanthropy Focus Supplement, featuring Nigel Mansell CBE's dedication to UK Youth

Leads with Nigel Mansell CBE's 25-year commitment to transforming the lives of young people with UK Youth, by raising millions and launching innovative programs LONDON, UNITED KINGDOM, February 21, 2025 /⁨EINPresswire.com⁩/ -- The supplement leads...

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers fourth milestone payment for this region to Basilea this year

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers fourth milestone payment for this region to Basilea this year

Allschwil, Switzerland, October 10, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that...

European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) and extension of market exclusivity triggers CHF 10 million milestone payment to Basilea

European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) and extension of market exclusivity triggers CHF 10 million milestone payment to Basilea

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 27, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and...

Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 25 million sales milestone payment to Basilea

Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 25 million sales milestone payment to Basilea

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, September 6, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial...

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service